title: Miltefosine Zentaris.
abstract: Zentaris (formerly Asta Medica) has developed and launched miltefosine, a phospholipid derivative, in various European countries [173324], [254947] and in Brazil in 1997 [332428], [366795] as a treatment for breast cancer. As of January 2002, phase III trials for treatment of leishmaniaisis were ongoing [435767]. In February 1999, Lehman Brothers predicted miltefosine would be launched for treatment of leishmaniasis in 2002, with peak sales expected in 2010 [319225].
authors.affiliation: Novartis, Centre de Recherche Santé Animale SA,, St. Aibin, Switzerland. ronald.kaminsky@ah.novartis.com
authors.forename: Ronald
authors.initials: R
authors.lastname: Kaminsky
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D006801:Humans; D007898:Leishmaniasis, Visceral / Q000188:drug therapy; D010767:Phosphorylcholine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology*; D013329:Structure-Activity Relationship; D014344:Trypanocidal Agents / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology*
chemical_list: D014344:Trypanocidal Agents; D010767:Phosphorylcholine; C039128:miltefosine